HomeCompareCLPBY vs EQR

CLPBY vs EQR: Dividend Comparison 2026

CLPBY yields 5.24% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLPBY wins by $10.5K in total portfolio value· pulled ahead in Year 4
10 years
CLPBY
CLPBY
● Live price
5.24%
Share price
$6.87
Annual div
$0.36
5Y div CAGR
22%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$58.3K
Annual income
$9,501.41
Full CLPBY calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — CLPBY vs EQR

📍 CLPBY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLPBYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLPBY + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLPBY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLPBY
Annual income on $10K today (after 15% tax)
$445.41/yr
After 10yr DRIP, annual income (after tax)
$8,076.20/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, CLPBY beats the other by $3,421.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLPBY + EQR for your $10,000?

CLPBY: 50%EQR: 50%
100% EQR50/50100% CLPBY
Portfolio after 10yr
$53.1K
Annual income
$7,488.51/yr
Blended yield
14.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CLPBY
Analyst Ratings
3
Buy
3
Hold
2
Sell
Consensus: Buy
Price Target
$14.45
+110.3% upside vs current
Range: $14.45 — $14.45
Altman Z
3.2
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLPBY buys
0
EQR buys
0
No recent congressional trades found for CLPBY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLPBYEQR
Forward yield5.24%5.87%
Annual dividend / share$0.36$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR22%15.8%
Portfolio after 10y$58.3K$47.8K
Annual income after 10y$9,501.41$5,475.61
Total dividends collected$32.7K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$14.45$70.35

Year-by-year: CLPBY vs EQR ($10,000, DRIP)

YearCLPBY PortfolioCLPBY Income/yrEQR PortfolioEQR Income/yrGap
1$11,339$639.30$11,380$679.82$41.00EQR
2$12,960$826.55$13,014$837.25$54.00EQR
3$14,944$1,077.08$14,961$1,036.20$17.00EQR
4← crossover$17,406$1,416.11$17,297$1,289.22+$109.00CLPBY
5$20,505$1,880.66$20,121$1,613.15+$384.00CLPBY
6$24,467$2,526.09$23,561$2,030.84+$906.00CLPBY
7$29,616$3,436.65$27,783$2,573.54+$1.8KCLPBY
8$36,432$4,743.10$33,013$3,284.39+$3.4KCLPBY
9$45,635$6,652.70$39,547$4,223.51+$6.1KCLPBY
10$58,331$9,501.41$47,791$5,475.61+$10.5KCLPBY

CLPBY vs EQR: Complete Analysis 2026

CLPBYStock

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Full CLPBY Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CLPBY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLPBY vs SCHDCLPBY vs JEPICLPBY vs OCLPBY vs KOCLPBY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.